SCHEMBL3484544

SCHEMBL3484544

Cc1ccc(Sc2cccc(O)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.50
BCL2 P10415 2/20 0.49
MCL1 Q07820 2/20 0.49
MGLL Q99685 3/20 0.46
NR1H2 P55055 1/20 0.44
SLC5A2 P31639 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
CA12 O43570 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CA2 P00918 1/20 0.42
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
CA5A P35218 1/20 0.42
CA9 Q16790 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
MLYCD O95822 1/20 0.42
HSD17B1 P14061 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30620468 1.00 ACHE (0.50) ACHEBCL2MCL1MGLLNR1H2
SCHEMBL2299032 0.85 NR1H2 (0.64) ACHEBCL2MCL1MGLLNR1H2
SCHEMBL31351862 0.85 MCL1 (0.47) ACHEBCL2MCL1SLC5A2MLYCD
SCHEMBL2239504 0.85 CA12 (0.58) ACHEMGLLNR1H2CA12ALDH1A1
SCHEMBL31281467 0.85 CA12 (0.58) ACHEMGLLNR1H2CA12ALDH1A1
SCHEMBL2865715 0.83 CA12 (0.50) BCL2MCL1MGLLNR1H2CA12
SCHEMBL822376 0.81 ACHE (0.48) ACHEBCL2MCL1MGLLSLC5A2
SCHEMBL31038384 0.81 ACHE (0.48) ACHEBCL2MCL1MGLLSLC5A2
SCHEMBL8373547 0.80 NR1H2 (0.56) ACHEBCL2MCL1MGLLNR1H2
SCHEMBL9658005 0.80 TSHR (0.50) BCL2MCL1MGLLNR1H2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117069555-A Synthetic method of substituted phenol 西安文理学院 2023-11-17 CN disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
EP-2049107-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES Genfit (FR) 2009-04-22 EP disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 ACHE 2077/4885BCL2 4461/4885MCL1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.